Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. April 2016 01:00 ET | Quelle: Addex Therapeutics

Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 11 April 2016 -...
15. März 2016 02:00 ET | Quelle: Addex Therapeutics

Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 15 March 2016 -...
11. Januar 2016 01:00 ET | Quelle: Addex Therapeutics

Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Additional analysis underlines the...
04. Januar 2016 01:00 ET | Quelle: Addex Therapeutics

Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} FDA Orphan Drug Status Validates the...
17. Dezember 2015 01:00 ET | Quelle: Addex Therapeutics

Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 17 December 2015 -...
15. Dezember 2015 01:00 ET | Quelle: Addex Therapeutics

Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 15 December 2015 -...
09. Dezember 2015 01:00 ET | Quelle: Addex Therapeutics

Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, December 9, 2015...
07. Dezember 2015 01:00 ET | Quelle: Addex Therapeutics

Addex Moves R&D Operations to Geneva's Campus Biotech

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, December 7, 2015 -...
25. November 2015 01:00 ET | Quelle: Addex Therapeutics

Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 25 November 2015...
23. November 2015 01:00 ET | Quelle: Addex Therapeutics

Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 23 November...

Vorherige Seite